TD Private Client Wealth’s Ionis Pharmaceuticals IONS Stock Holding History

TD Private Client Wealth’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.77K	Buy	98 +18	+23%	+$1.35K	﹤0.01%	1159
2026 Q1	$6.01K	Sell	80 -2	-2%	-$158	﹤0.01%	1158
2025 Q4	$6.49K	Buy	82 +2	+3%	+$151	﹤0.01%	1131
2025 Q3	$5.23K	Buy	80 +36	+82%	+$1.76K	﹤0.01%	1123
2025 Q2	$1.74K	Buy	+44	New	+$1.44K	﹤0.01%	1241
2021 Q4	–	Sell	-11	Closed	-$369	–	1215
2021 Q3	$369	Sell	11 -118	-91%	-$4.45K	﹤0.01%	1191
2021 Q2	$5.15K	Buy	129 +99	+330%	+$3.88K	﹤0.01%	955
2021 Q1	$1.35K	Sell	30 -73	-71%	-$4.07K	﹤0.01%	1030
2020 Q4	$5.82K	Buy	103 +19	+23%	+$947	﹤0.01%	879
2020 Q3	$3.99K	Hold	84	–	–	﹤0.01%	857
2020 Q2	$4.95K	Hold	84	–	–	﹤0.01%	840
2020 Q1	$3.97K	Hold	84	–	–	﹤0.01%	830
2019 Q4	$5.07K	Buy	+84	New	+$5K	﹤0.01%	814

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

TD Private Client Wealth's IONS Position: Q2 2026 in Review

TD Private Client Wealth increased its Ionis Pharmaceuticals (IONS) stake by 23% in Q2 2026, buying an estimated $1.35K and bringing the position to 98 shares worth $7.77K. The position accounts for ﹤0.01% of the portfolio, ranked #1159.

TD Private Client Wealth first reported a position in IONS in Q4 2019 and has held it in 13 quarters since. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

TD Private Client Wealth held 98 shares of Ionis Pharmaceuticals worth $7.77K as of Q2 2026.
TD Private Client Wealth bought 18 Ionis Pharmaceuticals shares in Q2 2026, an estimated $1.35K.
Ionis Pharmaceuticals made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1159 holding.
TD Private Client Wealth first reported a position in Ionis Pharmaceuticals in Q4 2019 and has held it in 13 quarters since.
513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.